- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06124274
Oral Contraceptive vs Menstrual Cycle Ex Vivo Model (OCEV)
The Effect of Menstrual Phase and Oral Contraceptives on Muscle Protein Metabolism
Despite comprising half the population, females are often left out of muscle research due to the impact of changing hormones during the menstrual cycle and when using oral contraceptives. This makes it hard to perform costly and invasive studies involving tracers to study muscle protein metabolism. Consequently, we lack a clear understanding of how these hormonal changes affect muscle growth.
There is a need for less invasive methods to study how sex hormones and oral contraceptives influence muscle protein metabolism. Ex vivo models, where serum from participants is applied to mouse muscle cell cultures, mimic the conditions of human muscle cells and can provide initial insights.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Daniel R Moore, PhD
- Phone Number: 4169464088
- Email: dr.moore@utoronto.ca
Study Contact Backup
- Name: Ines Kortebi, PhD Student
- Email: ines.kortebi@mail.utoronto.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5S2C9
- Recruiting
- Goldring Centre for High Performance Sport at the University of Toronto
-
Contact:
- Daniel R Moore, PhD
- Phone Number: 416-946-4088
- Email: dr.moore@utoronto.ca
-
Contact:
- Ines Kortebi, MSc
- Email: ines.kortebi@mail.utoronto.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI between 18.5-29.9 kg/m2 (I.e., non-obese).
- For OC users: on monophasic OCs for > 3 months prior to study enrollment
- For non-OC users: regular menstrual cycles length (25-35 days) for at least 3 months prior to study and at least 6 months off of OCs.
Exclusion Criteria:
- Chronic disease diagnosis (cardiovascular, thyroid, diabetes)
- Current or recent remission of cancer
- Regular use of NSAID (except low-dose aspirin), anticoagulants
- Use of prescription drugs that would impact metabolism, e.g. Statins, Lithium, Attention-Deficit/Hyperactivity Disorder (ADHD) medication.
- Insertion of intrauterine device (IUD) - exception: copper
- Use of ergogenic aids such as creatine
- Regular Tabacco use
- Use of illicit drugs (growth hormones, testosterone)
- For non-OC users: Use of oral contraceptives for > 6 months prior to study enrollment - to ensure return to regular menstrual cycle.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mid-Follicular Phase
7-11 days after onset of menses.
|
Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein).
Amino acid composition of the protein will be modelled off the composition of egg.
Leucine content will be enriched to 5% with [13 Carbon(13C)]-leucine.
|
Experimental: Mid-Luteal Phase
5-9 days after ovulation (as confirmed with ovulation test kits).
|
Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein).
Amino acid composition of the protein will be modelled off the composition of egg.
Leucine content will be enriched to 5% with [13 Carbon(13C)]-leucine.
|
Experimental: Active pill phase
10-20 days after starting new pill cycle.
|
Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein).
Amino acid composition of the protein will be modelled off the composition of egg.
Leucine content will be enriched to 5% with [13 Carbon(13C)]-leucine.
|
Experimental: Withdrawal phase
48hrs after last pill (during placebo pill phase).
|
Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein).
Amino acid composition of the protein will be modelled off the composition of egg.
Leucine content will be enriched to 5% with [13 Carbon(13C)]-leucine.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Protein Synthesis (Murine Cell-Based Experiments, ex-vivo experiments)
Time Frame: 60 minutes
|
Investigators will use human serum obtained from fasted and fed timepoints (-15, 20, 40 and 60 minutes following beverage consumption) to condition cell culture media (20% volume).
To determine the effects of using fasted and/or fed 'human-conditioned' culture media on cell protein synthesis, puromycin incorporation (measure of protein synthesis) will be measured via western blot and expressed relative to a no-serum control.
A two-way repeated measures ANOVA will be used to analyze outcomes with cycle stage and group (OC vs non-OC) used as factors
|
60 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urinary Measures (Muscle Protein Breakdown)
Time Frame: 6 hours
|
Investigators will measure urinary 3-methylhistidine (3MH) as an indirect marker of muscle protein breakdown over the course of the trial (6 hours) through pooled urine collection vs baseline urine.
|
6 hours
|
Whole-body protein synthesis
Time Frame: 6 hours
|
Investigators will measure the enrichment of [13 Carbon CO2 (13CO2)] in the breath by isotope ratio mass spectrometry (IRMS) in atom percent excess (APE).
The measurement of carbon dioxide production (VCO2) and stable isotope tracer enrichment in the breath allows for the assessment of the rate at which amino acids are used for energy (i.e., oxidized), rather than for protein synthesis (i.e., retained in the body) by calculating the fraction of expired CO2 that contains 13C.
Leucine retention (umol/kg) will then be calculated from the difference between the known amount of leucine provided (ingested) and leucine oxidation (as determined from 13CO2 breath enrichment).
|
6 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ines Kortebi, PhD Student, University of Toronto
- Study Director: Cassidy Tinline-Goodfellow, PhD (C), University of Toronto
- Study Director: Jonathan Aguilera, PhD Student, University of Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- OCEV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraceptives, Oral
-
BayerCompletedContraceptives, OralSlovakia, France, Germany, Hungary, Sweden, Czech Republic, Italy, Russian Federation, United Kingdom, Greece, Israel
-
BayerCompletedContraceptives, OralNetherlands
-
AstraZenecaCompleted
-
Columbia UniversityCompletedContraceptives, OralUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedContraceptives, Oral, Combined
-
Western University, CanadaRecruitingMenstrual Cycle | Oral ContraceptivesCanada
-
Kayseri Education and Research HospitalCompletedAdverse Effect of Oral Contraceptives, Subsequent Encounter
-
BayerCompletedContraception | Ovulation Inhibition | Contraceptives, OralUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedPharmacokinetics | Therapeutic Equivalency | Contraceptives, Oral
-
Anders Nyboe AndersenHvidovre University Hospital; Herlev HospitalUnknownOvarian Function and Reserve Parameters After Discontinuation of Long-term Use of Oral ContraceptionOral Contraceptives | Long-term Use | AMH | Ovarian Reserve ParametersDenmark
Clinical Trials on Protein tracer drink
-
Wageningen UniversityMaastricht University Medical Center; Top Institute Food and NutritionCompleted
-
Maastricht University Medical CenterTop Institute Food and NutritionCompletedMuscle Loss in ElderlyNetherlands
-
Lund UniversityLandstinget i Kalmar LänTerminated
-
Wageningen UniversityMaastricht University Medical Center; Top Institute Food and NutritionCompleted
-
Maastricht University Medical CenterMaastricht University Medical CenterRecruitingCritical Illness | Muscle WastingNetherlands
-
University of JenaCompleted
-
Wageningen UniversityFrieslandCampinaRecruiting
-
University of JenaGerman Federal Ministry of Education and ResearchCompleted
-
Maastricht University Medical CenterCompleted
-
Puleva BiotechUniversidad de GranadaUnknown